SPA
CPRX icon

Sherbrooke Park Advisers’s Catalyst Pharmaceutical CPRX Stock Holding History

Sherbrooke Park Advisers’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,785
Closed -$309K – 670
2024
Q4 		$309K Sell
14,785
-1,129
-7% -$24.3K 0.1% 390
2024
Q3 		$316K Buy
15,914
+4,279
+37% +$79.3K 0.07% 543
2024
Q2 		$180K Buy
+11,635
New +$181K 0.03% 783
2023
Q4 		– Sell
-10,544
Closed -$123K – 500
2023
Q3 		$123K Buy
+10,544
New +$141K 0.04% 439

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Sherbrooke Park Advisers's CPRX Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Catalyst Pharmaceutical (CPRX) in Q1 2025, closing a stake of 14,785 shares — an estimated $309K sold.

Sherbrooke Park Advisers first reported a position in CPRX in Q3 2023 and held it in 4 quarters. The position peaked at $316K in Q3 2024. 371 funds tracked by Wall St. Rank hold CPRX as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Catalyst Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 14,785 Catalyst Pharmaceutical shares in Q1 2025, an estimated $309K.
  • Sherbrooke Park Advisers first reported a position in Catalyst Pharmaceutical in Q3 2023 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Catalyst Pharmaceutical position peaked at $316K in Q3 2024.
  • 371 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.